Long-Term Efficacy and Safety of Paliperidone 6-Month Formulation: An Open-Label 2-Year Extension of a 1-Year Double-Blind Study in Adult Participants With Schizophrenia

BACKGROUND: Paliperidone palmitate 6-month (PP6M) demonstrated noninferiority to paliperidone palmitate 3-month in preventing relapse in patients with schizophrenia in a phase 3 double-blind (DB) study (NCT03345342). Here, we report long-term efficacy and safety results from a 2-year single-arm, ope...

Descripción completa

Detalles Bibliográficos
Autores principales: Najarian, Dean, Turkoz, Ibrahim, Knight, R Karl, Galderisi, Silvana, Lamaison, Hector F, Zalitacz, Piotr, Aravind, Suresh, Richarz, Ute
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Regular Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10464922/
https://www.ncbi.nlm.nih.gov/pubmed/37480362
http://dx.doi.org/10.1093/ijnp/pyad028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10464922/
https://www.ncbi.nlm.nih.gov/pubmed/37480362
http://dx.doi.org/10.1093/ijnp/pyad028

Ejemplares similares